WO1995024497A2 - Enzymatic preparation of polysaccharides - Google Patents
Enzymatic preparation of polysaccharides Download PDFInfo
- Publication number
- WO1995024497A2 WO1995024497A2 PCT/EP1995/000935 EP9500935W WO9524497A2 WO 1995024497 A2 WO1995024497 A2 WO 1995024497A2 EP 9500935 W EP9500935 W EP 9500935W WO 9524497 A2 WO9524497 A2 WO 9524497A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- udp
- hyaluronic acid
- phosphate
- triphosphate
- produced
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 30
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 30
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000002255 enzymatic effect Effects 0.000 title description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 84
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 81
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 81
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 79
- 238000006243 chemical reaction Methods 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 58
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 52
- 230000008569 process Effects 0.000 claims abstract description 44
- 239000002243 precursor Substances 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 235000000346 sugar Nutrition 0.000 claims abstract description 20
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 239000001913 cellulose Substances 0.000 claims abstract description 11
- 229920002678 cellulose Polymers 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 229920002101 Chitin Polymers 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 claims description 45
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 claims description 45
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 claims description 43
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 claims description 43
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims description 35
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 claims description 35
- 239000012510 hollow fiber Substances 0.000 claims description 33
- FZLJPEPAYPUMMR-FMDGEEDCSA-N N-acetyl-alpha-D-glucosamine 1-phosphate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(O)=O FZLJPEPAYPUMMR-FMDGEEDCSA-N 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 claims description 25
- 229950010772 glucose-1-phosphate Drugs 0.000 claims description 25
- 239000011541 reaction mixture Substances 0.000 claims description 20
- 101710128038 Hyaluronan synthase Proteins 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 14
- 230000002194 synthesizing effect Effects 0.000 claims description 14
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- YESDZLSBQGRWKM-KXWLUJSTSA-N (2s,3r,4s,5s)-4-[[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=NC=2C(=O)N=C(NC=21)N)OP(O)(=O)OP(O)(=O)O[C@@H]1[C@H](O)C(O)O[C@H](C(O)=O)[C@H]1O YESDZLSBQGRWKM-KXWLUJSTSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000001226 triphosphate Substances 0.000 claims description 7
- HXXFSFRBOHSIMQ-RWOPYEJCSA-L alpha-D-mannose 1-phosphate(2-) Chemical compound OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-RWOPYEJCSA-L 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims description 4
- 108010058683 Immobilized Proteins Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- 108010040093 cellulose synthase Proteins 0.000 claims description 4
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 4
- 102000005469 Chitin Synthase Human genes 0.000 claims description 3
- 108700040089 Chitin synthases Proteins 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 230000001698 pyrogenic effect Effects 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 238000004064 recycling Methods 0.000 abstract description 7
- -1 polymannuronan Polymers 0.000 abstract description 3
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 65
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 65
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 32
- 239000000872 buffer Substances 0.000 description 26
- 229940088598 enzyme Drugs 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 230000008929 regeneration Effects 0.000 description 21
- 238000011069 regeneration method Methods 0.000 description 21
- 150000002482 oligosaccharides Chemical class 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 17
- 229920001542 oligosaccharide Polymers 0.000 description 17
- 229910001629 magnesium chloride Inorganic materials 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 238000002523 gelfiltration Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000013009 Pyruvate Kinase Human genes 0.000 description 6
- 108020005115 Pyruvate Kinase Proteins 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 108010059712 Pronase Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 5
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 5
- 239000005373 porous glass Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 4
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 3
- 102100029640 UDP-glucose 6-dehydrogenase Human genes 0.000 description 3
- 101710191933 UDP-glucose 6-dehydrogenase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical group C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000784713 Cupido Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 101000980867 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Curved DNA-binding protein Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101000982319 Shallot virus X Uncharacterized ORF4 protein Proteins 0.000 description 2
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 108010061048 UDPacetylglucosamine pyrophosphorylase Proteins 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000235858 Acetobacter xylinum Species 0.000 description 1
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001535556 Enterococcus faecalis OG1RF Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 241000722985 Fidia Species 0.000 description 1
- 108010034448 GDPmannose dehydrogenase Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010038016 Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Chemical group CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940074731 ophthalmologic surgical aids Drugs 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007078 todd-hewitt medium Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Definitions
- the present invention relates to a process for the preparation of polysaccharides such as hyaluronic acid
- HA hyaluronate synthase
- Hyaluronic acid is a naturally occurring linear polysaccharide composed of repeating disaccharide units of glucuronic acid and N-acetylglucosamine linked by 3-1-3 and ⁇ -1-4 glycosidic bonds, as shown below:
- HA is present in all soft tissues of higher organisms, and in particularly high concentrations in the synovial fluid and vitreous humour of the eye (Laurent et al . (1991) Adv. Drug Deliv. Rev. 7:237) . In addition to fulfilling structural roles related to its lubricating and water-retaining properties, evidence is mounting that HA also plays an important role in a number of biological processes such as cell motility and cell-cell interactions (see Laurent et al . (1993) FASEB J. 6:2397 and Knudson et al . (1993) FASEB J. 7:1233 for recent reviews) .
- HA Biosvnthetic Pathway An important step in opening up the possibilities of genetic engineering is a definition of the HA biosynthetic pathway. Although no detailed genetic work has been carried out to identify each step in the biosynthetic pathway in streptococci, the succession of biochemical events can be put together based on knowledge of the biosynthesis of the two UDP-sugar precursors of HA gained from studies carried out in other organisms (Brede et al . (1991) J. Bacteriol . 173:7042; Mengin-Lecreuix et al. (1993) J. Bacteriol. 175:6150) and from some limited streptococcal studies
- the proposed biosynthetic pathway for HA is shown in Figure 1.
- the precursors, UDP-GlcA and UDP-NAcGlc are synthesized as side reactions of the glycolytic pathway starting from glucose-6-phosphate and fructose- 6-phosphate, respectively.
- Experiments carried out with radioactive glucose (0'Regan, unpublished data) have shown that about 5-7% of the glucose in the streptococcal culture medium is converted to HA.
- Metabolic engineering approaches designed to increase the flux towards HA could be fruitful in terms of obtaining yields that are more industrially viable.
- HA synthase is located in the plasma membrane. This has been shown by a number of different workers using various approaches. Markovitz and Dorfman ((1962) J. Biol. Chem. 238:273) first synthesized HA using streptococcal membranes. Prehm ((1983) Biochem J. 211:181 and 191) demonstrated the extracellular growth of the HA chain and that HA was not synthesized in the Golgi apparatus as are other members of the glycosaminoglycan family. Subsequently, Prehm ((1984) Biochem J.
- Hyaluronic acid was first synthesized from the activated sugar precursors UDP-GlcNAc and UDP-GlcA using cell extracts (Glaser et al . (1955) Proc. Natl . Acad.
- JP 02-231093 discloses the synthesis of hyaluronic acid by continuous enzyme reaction using 5'-UMP or its salts.
- HA oligosaccharides have been prepared by digestion of high-molecular weight HA with hyaluronidases and fractionation using standard chromatographic techniques such as those described by West et al. ((1989) Exp. Cell Res. 183:176-196) and EP 88 305255.7.
- West et al. ((1989) Exp. Cell Res. 183:176-196) and EP 88 305255.7.
- optimization of the technology could also permit synthesis of monodisperse HA oligosaccharides which might demonstrate improved biological activity when compared to the oligosaccharide fractions obtained by hyaluronidase digestion of HA followed by chromatographic separation.
- the optimization of. in vi tro technology could permit synthesis of novel polymers by modifying the catalytic site of the synthase to obtain enzymes which combine the sugar moieties in varying ways or incorporate alternative sugar components.
- immobilized HAS it is possible to produce HA that is free from contaminating proteins or infective agents.
- time and/or conditions of the reaction it is possible to produce a polymer of specific molecular weight,thus facilitating the synthesis of HA of various molecular weights depending upon the intended applications.
- the ability to regulate the reaction conditions makes it possible to control the polydispersity of the molecular weight, and thus produce a far more homogeneous product than is currently available.
- immobilized HAS it is possible to produce HA oligo ⁇ saccharides having defined molecular weights.
- UDP-glucuronic acid UDP-GlcA
- UDP-N-acetylglucosamine UDP-NAcGlc
- Another object of the present invention is to provide a method for purifying and isolating a protein fraction possessing HAS activity.
- Another object of the present invention is to provide a method of immobilizing HAS.
- Another object of the present invention is to provide a process for producing HA in vi tro with different molecular weights, comprising: incubating a protein or protein mixture active in synthesizing hyaluronic acid in a reaction mixture containinguridine-5' -triphosphate, glucose-1-phosphate, and N-acetylglucosamine-1-phosphate for a time and under reaction conditions suitable for the polymerization of UDP-glucuronic acid and UDP-N-acetylglucosamine to form hyaluronic acid, and suitable for the formation of UDP- glucuronic acid from UDP and glucose-1-phosphate and the formation of UDP-N-acetylglucosamine from UDP and N-acetylglucosamine-1-phosphate; and recovering said hyaluronic acid thus produced.
- Another object of the present invention is to provide a process for producing hyaluronic acid in vi tro, comprising: incubating a protein or protein mixture active in synthesizing hyaluronic acid in a reaction mixture suitable for the synthesis of hyaluronic acid from UDP- glucose and UDP-N-acetylglucosamine for a time and under conditions suitable for the polymerization of UDP- glucuronic acid and UDP-N-acetyl-glucosamine to form hyaluronic acid, and suitable for the formation of UDP- glucuronic acid from UDP and glucose-1-phosphate and for the formation of UDP-N-acetylglucosamine from UDP and N- acetylglucosamine-1-phosphate, wherein within said reaction mixture, uridine- 5' -triphosphate, glucose-1-phosphate, and N-acetyl- glucosamine-1-phosphate are contained within a single hollowfiber, and recovering said hyalur
- Yet another object of the present invention is to provide a process for .producing hyaluronic acid in vi tro , comprising: incubating a protein or protein mixture active in synthesizing hyaluronic acid in a reaction mixture suitable for the synthesis of hyaluronic acid from UDP-glucose and UDP-N-acetylglucosamine, wherein within said reaction mixture, uridine-
- reaction conditions in said first hollowfiber are suitable for the formation of UDP- glucuronic acid from uridine-5' -triphosphate and glucose-1-phosphate
- reaction conditions in said second hollowfiber are suitable for the formation of UDP-N-acetylglucosamine from uridine-5' -triphosphate and N-acetylglucosamine-1-phosphate, and recovering hyaluronic acid thus produced.
- Another object of the present invention is to provide a process for producing hyaluronic acid in vi tro, comprising: incubating an immobilized or non-immobilized protein or protein mixture active in synthesizing hyaluronic acid in alternate cycles with a mixture of uridine- 5' -triphosphate and glucose-1-phosphate, and separately with a mixture of uridine-5' -triphosphate and N-acetylglucosamine-1-phosphate, in either order, wherein each alternate cycle is for a time and under reaction conditions suitable for the polymerization of UDP-glucuronic acid and UDP-N-acetyl ⁇ glucosamine to form hyaluronic acid, wherein each alternate cycle is under reaction conditions suitable for the formation of UDP-glucuronic acid from uridine 5' -triphosphate and glucose-1- phosphate, and for the formation of UDP-N-acetylglucos ⁇ amine from uridine 5' -triphosphate and N-acetylglu
- Another object of the present invention is to provide a process for producing hyaluronic acid in vi tro, comprising: incubating an immobilized or non-immobilized protein or protein mixture active in synthesizing hyaluronic acid in alternate cycles with a mixture of uridine-5' -triphosphate and glucose-1-phosphate, and separately with a mixture of uridine-5' -triphosphate and N-acetylglucosamine-1-phosphate, in either order, wherein each alternate cycle is for a time and under reaction conditions suitable for the polymerization of UDP-glucuronic acid and UDP-N-acetyl- glucosamine to form hyaluronic acid, wherein said uridine-5' -triphosphate and glucose-1- phosphate are contained within a first hollowfiber under reaction conditions suitable for the formation of UDP-glucuronic acid, said uridine 5' -triphosphate and N-acetylglucos- amine-1-phosphate are contained within a second hollowfiber
- a further object of the present invention is to provide hyaluronic acid produced by any of the foregoing processes, wherein the molecular weight of said hyaluronic acid has a polydispersity of between about 1 and about 2.
- Another object of the present invention is to provide a pharmaceutical or cosmetic composition containing hyaluronic acid produced by any of the foregoing processes. Another object of the present invention is the use of hyaluronic acid produced by any of the foregoing processes for the preparation of a pharmaceutical or cosmetic composition.
- a further object of the present invention is to provide a process for producing cellulose in vi tro, comprising: incubating cellulose synthase in a reaction mixture containing uridine-5' -triphosphate and glucose-1- phosphate for a time and under reaction conditions suitable for the synthesis of cellulose, and suitable for the formation of UDP-glucose from uridine- 5' triphosphate and glucose-1-phosphate; and recovering cellulose thus produced.
- Yet a further object of the present invention is to provide a process for producing polymannuronic acid in vi tro, comprising: incubating GDP-mannuronic acid polymerase in a reaction mixture containing guanosine-5' -triphosphate and mannose-1-phosphate for a time and under reaction conditions suitable for the synthesis of polymannuronic acid, and suitable for the formation of GDP-mannuronic acid from guanosine-5' -triphosphate and mannose-1- phosphate, and recovering polymannuronic acid thus produced.
- a still further object of the present invention is to provide a process for producing chitin in vi tro, comprising: incubating chitin synthase in a reaction mixture containing uridine-5' -triphosphate and N-acetylglucos- amine-1-phosphate for a time and under reaction conditions suitable for the synthesis of chitin, and suitable for the formation of UDP-N-acetylglucosamine from uridine-5' -triphosphate and N-acetylglucosamine-1- phosphate, and recovering chitin thus produced.
- Another object of the present invention is to provide a process for producing a polysaccharide in vi tro , comprising: incubating the sugar-nucleotide synthase or polymerizing enzyme for said polysaccharide in a reaction mixture containing sugar precursors for said polysaccharide and nucleotide triphosphate carriers for said sugar precursors for. a time and under reaction conditions suitable for the synthesis of said polysaccharide, and suitable for the formation of sugar- nucleotide precursors from said nucleotide triphosphate carriers and said sugar precursors, and recovering said polysaccharide thus produced.
- Figure 1 Shows the proposed biosynthetic pathway for hyaluronic acid.
- FIG. 2 Shows separation of an extract of digitonin-solubilized membranes of S. equisimilis D181 by anion exchange chromatography. Membranes were loaded with HA by incubating with UDP-GlcA and UDP-NAcGlc. After adding PEG and phase separation, the supernatant is loaded on a DE.AE column.
- Bottom SDS-PAGE analysis of the proteins of fractions 10 - 30.
- elution profile hyaluronate synthase activity (boxes) determined according to Prehm ( (1983) Biochem. J. 211:181 and 191) ; NaCl gradient (triangles) .
- FIG. 3 Shows HA produced by immobilized HAS.
- Immobilized HAS (5 mg of protein/g solid support) was incubated in a 10 ml solution containing 100 mM phosphate buffer, pH 7.5, 1 mM DTT, 10 mM MgCl 2 , 1 mM UDP-GlcA and 1 mM UDP-NAcGlc for 2 hours at 37°C.
- HA was liberated from the immobilized HAS by adding NaCl to a final concentration of 1 M.
- Immobilized HAS was removed by low centrifugal force (500 x g) , and the HA was analysed by SDS-PAGE. Electrophorectic conditions and staining are those described by Moller et al.
- Figure 4 Shows enzymatic synthesis of hyaluronic acid.
- the figure demonstrates the incorporation of glucose-1-P in HA using a multienzyme reaction with sugar nucleotide regeneration.
- the reaction was carried out in 1 ml containing 100 mM HEPES buffer, pH 7.5, 10 mM MgCl 2 , 4 mM DTT, 50 mM KC1, 10 mM Glc-l-P, 10 mM GlcNAc-1-P, 1 mM UTP, 20 mM PEP, 0.5 mM NAD, 50 LDH, 50 PK, 50 U/ml inorganic pyrophosphatase, 2 U/ml UDP-GlcNAc pyrophosphorylase, 0.5 U UDP-Glc dehydrogenase, 1 U/ml UDP-Glc pyrophosphorylase, and 200 ⁇ g HAS for 48 hours at 25°C.
- the solution was treated with proteinase K and pronase E (see above) , and proteins were precipitated by adding TCA to 5% (v/v) .
- the solution was clarified by centrifugation and loaded on a Sepharose CL-4B column, eluted with PBS, and the radioactivity of each fraction was counted. About 90% of the starting amount of Glc-1- P is incorporated in HA.
- FIG. 5 Shows molecular weight determination by GPC-MALLS of the HA produced in vi tro .
- HA was produced as described in Figure 4, using non-radioactively labelled Glc-l-P. After TCA precipitation of the proteins and centrifugation, the supernatant was dialysed (molecular weight, cut-off 5000) extensively against water, lyophilized, resuspended in water, and loaded for GPC-MALLS.
- Figure 6 Scheme showing enzymatic synthesis of HA with regeneration of sugar nucleotides.
- Figure 7 Scheme showing enzymatic synthesis of HA with regeneration of sugar nucleotides in a hollowfiber enzyme reactor.
- Figure 8 Scheme showing enzymatic synthesis of cellulose with regeneration of sugar nucleotides.
- Figure 9 Scheme showing enzymatic synthesis of polymannuronic acid with regeneration of sugar nucleotides.
- Figure 10 Scheme showing enzymatic synthesis of chitin with regeneration of sugar nucleotides.
- HAS can be purified according to the following protocol:
- Streptococcal strains such as Streptococcus equisimilis D181 strain obtained from the Rockefeller
- pyogenes WF50 or WF51 a Pasteurella mul tocida Carter type A strain 880; recombinant bacterial strains containing a vector or vectors encoding HA synthase, such as the plasmid pPD41, which codes for the streptococcal HA synthase and UDP-Glc dehydrogenase and an undescribed stretch of streptococcal genomic DNA; bacteria containing such plasmids, like Escherichia coli and Enterococcus faecalis OG1RF; eukaryotic cells, such as fibroblats, chondrocytes, and virally transformed cells (e.g., SV40 transformed 3T3 fibroblasts and RSV transformed chondrocytes) , are grown in the desired volume of Todd-Hewitt medium, or any other conventional nutritional medium, at a temperature of between 30°C and 40°C, preferably 37°C, until a final OO 600n
- the cells are pelleted by centrifugation at 6,000 x g for 15 minutes, at 4°C, washed once in a suitable buffer, such as a standard cold phosphate buffered saline (PBS) , and resuspended in a final volume of between 1 and 100 ml, preferably 20 ml, of cold PBS containing approximately ImM dithiothreitol (DTT) .
- a suitable buffer such as a standard cold phosphate buffered saline (PBS)
- DTT ImM dithiothreitol
- the suspension is treated by procedures that cause the destruction of the cells, such as sonication at 0°C, and under conditions that ensure that cell destruction is total while minimizing inactivation of the enzyme.
- Various different sonication conditions can be employed, but the most suitable have proved to be 15 minutes at 120 watts. Unless otherwise stated, operations should be carried out at 4°C.
- cells can be disrupted by French press treatment (e.g., 1000 bar) ; by treatment with glass beads; or by digestion with cell wall degrading enzymes.
- French press treatment e.g., 1000 bar
- One gram of cells in 10 ml standard phosphate buffered saline (PBS) solution or in 50 mM NaHP0 4 /KH 2 P0 4 , PH 6.9, 10 mM MgCl 2 , 5 mM DTT, 30% raffinose can be digested with lysozyme (1 mg/ml, 37°C, 60 min) , mutanolysin (50 ⁇ g/ml, 37°C, 60 min) , muraminidase (0.1 mg/ml, 37° C, 60 min) or phage lysin (50,000 Units, 37°C, 60 min) .
- the protoplasted cells can be lysed by resuspending in hypotonic buffers, such as Tris-malonate or 50 mM NaHP0 4 /KH 2 P0 4 , PH 6.9, 10 mM MgCl 2 , 5 mM DTT. Additionally, to ensure lysis after digestion, sonication, treatment with glass beads, or French press passage can be employed.
- hypotonic buffers such as Tris-malonate or 50 mM NaHP0 4 /KH 2 P0 4 , PH 6.9, 10 mM MgCl 2 , 5 mM DTT.
- the sediment containing the cell membranes is resuspended by mild sonication, for instance 30 seconds at 20 watts, in a small volume of Tris-malonate buffer, 50 mM, pH 7, or any other suitable buffer containing approximately 1 mM DTT, such as PBS. 50 mM NaHP0 4 /KH 2 P0 4 , pH 6.9, 150 mM NaCl, 10 mM MgCl 2 , 5mM DTT, 10% glycerol, can also be used.
- the protein concentration is then determined, and the suspension is diluted in the same buffer at a final protein concentration of between about 1 and 10 mg/ml, preferably about 3 mg/ml.
- a mild detergent such as digitonin or dodecyl maltoside is added to give a final concentration of between 0.5 and 2%, preferably 1%.
- the suspension is stirred for about one hour at 0°C and then ultracentrifuged at 100,000 x g for 30 minutes, or under similar conditions, to separate membrane fragments.
- the synthase can be separated from the detergent in a number of ways.
- solubilized membranes can be directly loaded on an ion exchange chromatography column.
- HAS can be affinity purified using poly- or monoclonal antibodies against the HA synthase.
- These antibodies can be immobilized on a solid support.
- a preferred method is that described by Parish et al. ((1986) Anal. Biochem. 156:594-602) whereby separation is achieved by adding polyethylene glycol (PEG) 6000.
- PEG polyethylene glycol
- the protein can be "loaded” with newly-synthesized HA to increase its affinity for the aqueous phase.
- the following compounds are added to 5 ml of the supernatant resulting from step 6: between 0.2 and 5 ml of a 50% solution of PEG 6000, preferably 1 ml; 0.05 ml of a solution of 1 M MgCl 2 , between 0.5 and 5 mg of UDP-N-acetylglucosamine and UDP-glucuronic acid, preferably 2 mg of each.
- the mixture is then incubated under conditions favouring the synthesis of HA, for example at 37°C for 30 minutes, and is then rapidly cooled to 0°C in an iced salt bath.
- a further aliquot of 50% PEG 6000 (1 ml) is then added and the solution is vortexed. At this point, the suspension will look turbid, signifying that phase separation has occurred.
- the suspension is again ultracentrifuged, for example at 100,000 x g for 30 minutes at 4°C-
- the active HAS can be separated from the mixture in various ways, including inverse phase chromatography, such as HPLC.
- the supernatant should preferably be passed through an ion exchange HPLC column, such as a Waters DE-AE-protein Pak SWP (7.5 cm x 7.5 mm) column, which has previously been equilibrated with a suitable buffer, such as 50 mM Tris-malonate, pH 7.0, containing a suitable quantity of detergent, such as digitonin, at a final concentration of between 0.01% and 1%, preferably 0.5%.
- a suitable buffer such as 50 mM Tris-malonate, pH 7.0
- detergent such as digitonin
- the column is washed with starting buffer, and proteins can be eluted by gradually increasing the salt concentration of the buffer, for example from 0 M to 0.5 M NaCl in 30 minutes, with a constant flow rate of 1 ml/min. Fractions can be gathered at a desired volume, but a volume of 1 ml is advisable.
- each single fraction contains active HAS.
- analyses include determining absorbance at 280 n , conductivity, and HAS activity by means of radiolabelled precursors, as described by Prehm ((1983) Biochem. J. 211:181-189) .
- the protein pattern of each fraction can be analysed by polyacrylamide gel electrophoresis, following precipitation of the proteins from a fixed volume of each fraction, for example 200 ⁇ l, by a standard technique, such as that described by Wessel and Fl ⁇ gge ((1984) Anal. Biochem. 138:141-143) .
- HAS peak activity resides in the fractions containing a substantially pure protein of approximately 42 kDa, corresponding to the HAS described above.
- HAS can be immobilized to solid supports (matrices) such as those described by Scouten ( (1987) Meth. Enzym. 135:30-65) and used for the in vi tro synthesis of HA.
- matrices such as those described by Scouten ( (1987) Meth. Enzym. 135:30-65) and used for the in vi tro synthesis of HA.
- Scouten (1987) Meth. Enzym. 135:30-65
- a coupling buffer such as NaHC0 3 (0.1 M, pH 8.3) containing NaCl
- any other suitable buffer such as borate buffer (O.IM, pH 8.3) containing NaCl (0.5M) . It is possible to couple 1 to 10 mg, preferably 5 mg, of isolated and purified HAS to 1 g of solid support.
- step 2 The solution resulting from step 1 is mixed with a solid support, such as CNBr-activated Sepharose 4B (Pharmacia) , which has previously been washed with 1 mM HCI (200 ml per 1 g of support) , or any other suitable kind of support, and incubated under conditions that will allow the HAS to be coupled to the support, for example 16 hours at 4°C using an end-over-end or similar mixer.
- a solid support such as CNBr-activated Sepharose 4B (Pharmacia)
- 1 mM HCI 200 ml per 1 g of support
- any other suitable kind of support or any other suitable kind of support
- step 3 The support resulting from step 2 is transferred into a solution containing a blocking agent such as 1 M ethanolamine, 0.2 M glycine, or any other suitable blocking agent, and incubated under conditions that will allow the remaining active groups to be blocked, for instance 2 hours at room temperature.
- a blocking agent such as 1 M ethanolamine, 0.2 M glycine, or any other suitable blocking agent
- the support resulting from step 3 is washed at room temperature with the coupling buffer, or with any other suitable buffer, for example PBS or 50 mM NaHP0 4 /KH 2 P0 4 , PH 6.9, 150 mM NaCl, 10 mM MgCl 2 , 5 mM DTT, 10% glycerol, to free it from any excess protein and from the blocking agent.
- the coupling buffer or with any other suitable buffer, for example PBS or 50 mM NaHP0 4 /KH 2 P0 4 , PH 6.9, 150 mM NaCl, 10 mM MgCl 2 , 5 mM DTT, 10% glycerol, to free it from any excess protein and from the blocking agent.
- the support resulting from step 4 is stored at 4°C in a storage solution such as PBS, or any other suitable storage solution.
- hyaluronic acid of varying molecular weight for various applications using purified HAS or purified and immobilized HAS.
- molecular weight fractions in the range of from about 400 to 50,000 Daltons, and those greater than about 2 x 10 6 Daltons.
- HAS refers to pure HAS, a substantially pure protein fraction containing HAS, or a membrane fraction exhibiting HA synthetic activity.
- purified HAS or purified and immobilized HAS is diluted in 100 mM HEPES buffer, pH 7.5, or any other suitable buffer, to a final protein concentration of between 0.01 and 1.0 mg/ml, preferably 0.1 mg/ml.
- Dithriothreitol is added to the solution to a final concentration of about 1 mM, MgCl 2 to a final concentration of about 10 mM, UDP-GlcA and UDP-NAcGlc, both to concentrations of between 0.01 and 5 mM, preferably 1 mM.
- the mixture is then incubated at a temperature of between 30°C and 40°C, preferably 37°C, for long enough to allow the synthesis of HA, for example, two hours.
- the mixture is resuspended in a highly saline solution, for example 1 M NaCl, so as to allow the release of HA, and the reaction is stopped by removing immobilized HAS by using low centrifugal forces, for example 500 x g.
- the reaction is stopped by adding proteinase K and pronase E (from 5 to 100 ⁇ g/ml, but preferably 50 ⁇ g/ml) , and incubating for 30 min at 37° C.
- the reaction mixture is then subjected to gel filtration on a Sephadex G-25 column, or any other suitable gel permeation column, such as Fractogel HW50, Biogel P-4, Biogel P-6, or Ultrogel AcA202.
- the HA is eluted with PBS or any other suitable buffer.
- radiolabelled precursors such as those described by Prehm ((1983) Biochem. J. 211:181-189) can be used.
- the HA product can be analysed by SDS-PAGE, as described by Moller et al. ((1993) Anal. Biochem. 209:169-175) , by GPC-MALLS
- the molecular weight of the HA synthesized in vi tro by the use of HAS can be varied by modifying the incubation times and/or reaction conditions.
- the reaction conditions that can be varied to influence the molecular weight of the final HA product include, but are not limited to, pH, temperature, duration, etc.
- the pH can be varied between 4.2 and 8.9; a decrease in the pH produces a decrease in the molecular weight of the HA.
- the temperature can be varied between 10°C and 40°C; the lower the temperature, the lower the molecular weight of the HA produced.
- the time range for incubation is between 5 and 120 minutes; shorter incubation times result in HA of lower molecular weight.
- HA having a molecular weight of about 500,000 Daltons requires an incubation time of approximately 30 min at 25°C.
- HA oligosaccharides and polysaccharides having predefined molecular weights preferably from about 400 to about 50,000 Daltons, and with given starting and terminating saccharide units, using immobilized HAS and the UDP-precursors UDP-GlcA and UDP-NAcGlc (hereafter designated "A" or "B", respectively) .
- the first (or last) reaction step is started (terminated) with one of the two UDP-precursors A or B.
- the molecular weight of the hyaluronic acid oligosaccharide or polysaccharide can be controlled by varying the number of times the immobilized HAS is incubated with UDP-GlcA or UDP-NAcGlc.
- immobilized HAS is diluted in 100 mM HEPES buffer, pH 7.5, or in any other suitable buffer, to a final concentration of between 0.1 and 10.0 mg/ml, preferably 1.0 mg/ml .
- dithiothreitol is added to this suspension to a final concentration of about 1 mM and MgCl 2 to a final concentration of about 10 mM.
- a UDP-precursor is added to the suspension to a final concentration of between 0.01 and 5 mM, preferably 1 mM.
- the mixture is incubated under suitable conditions, for example at 25°C for 5 minutes.
- step 3 The mixture resulting from step 2 is washed with 100 mM HEPES buffer, pH 7.5, or any other suitable buffer, on a porous glass filter (e.g., with a porosity of G3) , and the matrix is recovered.
- a porous glass filter e.g., with a porosity of G3
- the matrix is resuspended in 100 mM HEPES buffer, pH 7.5, or in any other suitable type of buffer, to a final protein concentration of between 0.1 and 10.0 mg/ml, preferably 1.0 mg/ml.
- To this suspension are added dithiothreitol to a final concentration of about 1 mM and MgCl 2 to a final concentration of about 10 mM.
- the alternate UDP-precursor (A or B) is added to a final concentration of between 0.01 and 5 mM, preferably 1 mM.
- the mixture is washed with HEPES, or any other suitable buffer, on a porous glass filter (e.g., porosity G3) , and the matrix is recovered.
- a porous glass filter e.g., porosity G3
- the matrix is resuspended and incubated in a highly saline solution, so as to facilitate the release of the HA oligosaccharide chain from the immobilized HAS, for example in NaCl (1 M) for 30 minutes at 25°C.
- the matrix is then washed again on a porous glass filter.
- the filtered product is then subjected to gel filtration on a Sephadex G-25 column or any other suitable gel filtration medium such as Fractogel HW50, Biogel P-4, Biogel P-6, or Ultrogel AcA202.
- the HA is eluted with PBS or any other suitable buffer.
- radiolabelled precursors can be used, as described by Prehm ((1983) Biochem. J. 211:181-189) .
- the HA thus produced can be analysed by SDS-PAGE, as described by Moller et al. ((1993) Anal. Biochem. 209:169-175), GPC-MALLS, or by any other method capable determining the molecular weight of HA.
- UDP can be recycled, and the UDP-precursors UDP-glucuronic acid (UDP-GlcA) and UDP-N-Acetyl- glucosamine (UDP-NAcGlc) employed in in vi tro HA synthesis can be enzymatically regenerated, starting from glucose - 1 -phosphate (Glc-l-P) and N-Acetylglucosamine-1-phosphate (NAcGlc-1-P) , phosphoenolpyruvate (PEP) , and catalytic quantities of NAD + and UDP. Similar methods have been described by Ichikawa et al . ((1992) Anal. Biochem.
- purified HAS or purified and immobilized HAS is diluted in a suitable buffer, for example 100 mM HEPES buffer, pH 7.5.
- step 2 To the solution resulting from step 1, the following reagents are added to concentrations of approximately: DTT (between 0.1 and 10 mM, preferably 4 mM) , MgCl 2 (between O.IM and 5mM, preferably 10 mM) , KC1 (between 0.1 M and 100 mM, preferably 50 mM) , UTP
- NADH (each between 0.01 and 1 mM, preferably 0.1 mM) ,
- Glc-l-P and NAcGlc-1-P (each between 2 mM and 100 mM, preferably 10 mM) , PEP (between 2 and 50 mM) pyruvate kinase (PK) and lactate dehydrogenase (LDH) (each between 10 and 1000 U/ml, preferably 50 U/ml) , inorganic pyrophosphorylase (PPase) (between 1.2 and 120 U/ml, preferably 50 U/ml) , UDP-Glc pyrophosphorylase (between 0.1 and 10 U, preferably 1 U) , UDP-GlcNAc pyrophosphorylase (between 0.1 and 20 U, preferably 2 U) , and UDP-Glc dehydrogenase (between 0.1 and 10 U/ml, preferably 1 U/ml) .
- the enzymes can also be immobilized on solid supports as described in Example 2, or separated from the HAS by compartmenting them,
- step 3 The solution resulting from step 2 is incubated under suitable reaction conditions, preferably for 48 hours at 25°C, in order to reduce the risk of oxidation of the reaction components, preferably under anaerobic conditions, for example under argon or nitrogen.
- the reaction is stopped by removing the enzymes by using low centrifugal forces, for example 500 x g, when they are immobilized, or by removing the compartmenting system, for example by removing the hollowfiber system, when the enzymes are entrapped within a hollowfiber.
- the reaction is stopped by adding proteinase K and pronase E (from 5 to 100 ⁇ g/ml, but preferably 50 ⁇ g/ml) , and incubating for 30 min at 37°C.
- step 4 The solution resulting from step 3 is chromatographed on a Sephadex G-25 gel permeation column, or any other suitable gel permeation medium such as Fractogel HW50, Biogel P-4, Biogel P-6, or Ultrogel AcA202.
- the HA is eluted with PBS or any other suitable buffer.
- labelled precursors can be used, such as those described by Prehm ((1983) Biochem. J. 211:181-189) .
- the HA thus produced can be analysed by SDS-PAGE, as described by Moller et al . ((1993) Anal. Biochem. 209:169-175), GPC-MALLS, or by any other method capable determining the molecular weight of HA.
- SDS-PAGE as described by Moller et al . ((1993) Anal. Biochem. 209:169-175), GPC-MALLS, or by any other method capable determining the molecular weight of HA.
- GPC-MALLS or by any other method capable determining the molecular weight of HA.
- the results of the incorporation of radioactively labeled Glc-l-P in HA are shown in Figure 4.
- the HA produced in this way has all the necessary characteristics to be used advantageously in pharmaceutical applications and other related applications, being extremely pure compared to hyaluronic acid purified from conventional sources, and being free from any significant quantities of contaminating proteins, pyrogenic or inflammatory substances, or viruses.
- HA oligosaccharides and polysaccharides of predefined molecular weights in the range of from about 400 Daltons to about 50,000 Daltons, with given starting and terminating saccharide units, can be produced in a manner similar to that described in Example 4, taking advantage of the cost-effectiveness of UDP recycling and enzymatic regeneration of UDP-GlcA and UDP-NAcGlc from the relatively inexpensive precursors Glc-l-P and NAcGlc-1-P, as described in Example 5.
- immobilized or non-immobilized pure HAS, substantially pure HAS, or a membrane fraction exhibiting HA synthetic activity can be alternately contacted with UDP-GlcA and UDP-NAcGlc regenerating systems under conditions suitable for HA synthesis.
- HA oligosaccharides and polysaccharides of defined molecular weights can be cheaply produced.
- HAS can be alternately introduced into UDP-GlcA and UDP- NAcGlc regenerating reaction media as described in Example 5, for example by successively recovering immobilized HAS, or compartmentalizing HAS in, for example, a hollowfiber containing HAS in HA synthesis reaction medium.
- the molecular weight of the HA oligosaccharide or polysaccharide can be controlled by varying the number of times the HAS is incubated with the UDP-GlcA and UDP-NAcGlc regenerating systems.
- SUBSTITUTESHEET(RULE26j " purified HAS, or purified and immobilized HAS, is diluted in 100 mM HEPES buffer, pH 7.5, or in any other suitable buffer, to a final concentration of between 0.1 and 10.0 mg/ml, preferably 1.0 mg/ml.
- Dithiothreitol is added to the solution to a final concentration of about 1 mM and MgCl 2 to a final concentration of about 10 mM.
- Two hollowfiber systems are employed, one containing the precursors, enzymes, cofactors, etc., required for the regeneration of UDP-GlcA; the other containing the precursors, enzymes, cofactors, etc., required for the regeneration of UDP-NAcGlc.
- the buffer system, precursor concentrations, enzyme concentrations, cofactor concentrations, etc. are the same as described in step 2 of Example 5 in the respective hollowfibers.
- the first hollowfiber containing the regeneration system for either UDP-Glc or UDP-NAcGlc, as desired, is introduced into the reaction vessel, and the mixture is incubated under suitable conditions, for example at 25°C for 5 minutes.
- the first hollowfiber is removed, and the second hollowfiber containing the alternate UDP-precursor regeneration system is introduced into the reaction vessel and incubated as for the first hollowfiber.
- the matrix is recovered from the reaction vessel by washing on a porous glass filter (e.g., porosity G3) , and the matrix is recovered. 7.
- the matrix is resuspended and incubated in a highly saline solution so as to facilitate the release of the HA oligosaccharide chain from the immobilized HAS, for example in NaCl (1 M) for 30 minutes at 25°C.
- the matrix is then washed again on a porous glass filter.
- the filtered product is then subjected to gel filtration.
- gel filtration media can be used.
- a suitable gel filtration medium is Sephadex G-10 or any other similar gel filtration medium such as Biogel P-2 or Sephadex G-15.
- a suitable gel filtration medium is Fractogel HW40 or any other similar gel filtration medium such as Fractogel HW50.
- the HA is eluted with PBS or any other suitable buffer.
- the hollow fiber is removed, and the reaction is stopped by adding proteinase K and pronase E (from 5 to 100 ⁇ g/ml, but preferably 50 ⁇ g/ml) and incubating for 30 min at 37° C.
- the reaction mixture is then subjected to gel filtration.
- different gel filtration media can be used.
- a suitable gel filtration medium is Sephadex G-10 or any other similar gel filtration medium such as Biogel P-2 or Sephadex G-15.
- a suitable gel filtration medium is Fractogel HW40 or any other similar gel filtration medium such as Fractogel HW50.
- the HA is eluted with PBS or any other suitable buffer.
- radiolabelled precursors can be used, as described by Prehm ((1983) Biochem. J. 211:181-189) .
- the HA thus produced can be analysed by SDS-PAGE, as described by Moller et al . ((1993) Anal. Biochem. 209:169-175) , GPC-MALLS, or by any other method capable determining the molecular weight of HA.
- HA can also be synthesized using a system wherein UDP is recycled and UDP-GlcA and UDP-NAcGlc are enzymatically regenerated during the synthesis of HA in vitro by employing a "two pot system" wherein hollowfibers are employed to compartmentalize the recycling and regeneration reactions.
- a typical reaction protocol is as follows.
- Two hollowfiber systems are submerged in a reaction solution containing HAS, DTT, and MgCl 2 , as described in Example 3.
- One hollowfiber contains the precursors, enzymes, cofactors, etc. required for the regeneration of UDP-GlcA; the other hollowfiber contains the precursors, enzymes, cofactors, etc. required for the regeneration of UDP-NAcGlc. This is schematically shown in Figure 6.
- the enzymes required for the regeneration of the UDP-precursors can be contained in a single hollowfiber system which is submerged in an HAS-containing reaction solution.
- the buffer system, precursor concentrations, enzyme concentrations, cofactor concentrations, etc. are the same as described in step 2 of Example 5.
- the reaction solution is incubated under suitable reaction conditions, preferably for 48 hours at
- reaction components preferably under anaerobic conditions, for example under argon or nitrogen.
- the reaction is stopped by removing the enzymes entrapped within the hollowfiber.
- reaction solution containing HAS is treated with proteinase K and pronase E (from 5 to 100 ⁇ g/ml, preferably 50 ⁇ g/ml) , and incubated for 30 min at 37°C.
- the enzyme is removed by using low centrifugal forces, for example 500 x g.
- step 4 The solution resulting from step 4 is chromatographed on a Sephadex G-25 gel permeation column, or any other suitable gel permeation medium such as Fractogel HW50, Biogel P-4, Biogel P-6, or Ultrogel AcA202.
- the HA is eluted with PBS or any other suitable buffer.
- labelled precursors can be used, such as those described by Prehm ( (1983) Biochem. J. 211:181-189) .
- the HA thus produced can be analysed by SDS-PAGE, as described by Moller et al . ((1993) Anal. Biochem. 209:169-175), GPC-MALLS, or by any other method capable determining the molecular weight of HA.
- Cellulose can be synthesized in vi tro using the sugar precursor UDP-glucose (UDP-Glc) and cellulose synthase, which can be isolated from Acetobacter xylinum or protoplasted plant cells (Wong et al . (1990) Proc. Natl Acad. Sci . USA 87:8130-8134) .
- UDP-Glc sugar precursor UDP-glucose
- cellulose synthase which can be isolated from Acetobacter xylinum or protoplasted plant cells (Wong et al . (1990) Proc. Natl Acad. Sci . USA 87:8130-8134) .
- the reaction system includes cellulose synthase, and the regeneration system for UDP- Glc includes glucose-1-P, phosphoenolpyruvate, MgCl 2 , DTT, pyruvate kinase, UDP-Glc pyrophosphorylase, and inorganic pyrophosphatase. Reaction conditions are similar to those described in Example 5.
- PM Polymannuronic acid
- alginate-producing bacterial strains such as Pseudomonas aeruginosa , P. fluoreszens, and AzotoJacter vinelandi .
- PM can be synthesized in vi tro using GDP-mannuronic acid polymerase (Gacesa et al . (1990) Psedomonas Infection and Alginates, Biochemistry, Genetics and Pathology. Chapman and Hall, London) .
- the reaction system includes GDP-mannuronic acid polymerase, and the regeneration system for GDP-mannuronic acid contains mannose-1-P, phosphoenolpyruvate, MgCl 2 , DTT, pyruvate kinase, GDP- mannose pyrophosphorylase,- GDP-mannose dehydrogenase, and inorganic pyrophosphatase. Reaction condition are similar to those described in Example 5.
- chitin can be synthesized in vitro using the sugar precursor UDP-N-Acetylglucos-amine
- UDP-NAcGlcA chitin synthase
- Saccharomyces cerevisiae a cloned enzyme from S. cerevisiae can be used (Silverman (1989) Yeast 5:459-467; Bulawa (1992) Mol . Cell Biol. 12:1764- 1776; Cabib et al . (1983) Proc. Natl . Acad. Sci . USA 80:3318-3321) .
- the regeneration system for UDP-NAcGlcA includes N-acetylglucosamine-1-P, phosphoenolpyruvate, MgCl 2 , DTT, pyruvate kinase, UDP-NAcGlc pyrophosphorylase, and inorganic pyrophosphatase. Reaction conditions are similar to those described in Example 5.
- compositions containing an effective amount of hyaluronic acid prepared according to the methods of the present invention, alone or in association with one or more active principles, pharmacologically acceptable carriers, diluents, or excipients, can be used advantageously in the medical/pharmaceutical field, for example in ophthalmology, in the area of tissue repair, and in rheumatology.
- These pharmaceutical compositions can be administered by the topical, intra-articular, ophthalmic, systemic, and peritoneal routes.
- Such pharmaceutical compositions have been described in European Patent 0 138 572 Bl, and in PCT publication WO 92/18543.
- compositions typically contain hyaluronic acid in an amount of from about 0.1 mg/ml to about 100 mg/ml .
- compositions can be in the form of creams, gels, ointments, bandages, and gauzes.
- ophthalmic use they can be in the form of eye drops, viscoelastic surgical aids, lenses, etc.
- compositions for intravenous or intramuscular adminstration are suitable, such as ampoules or vials.
- compositions containing HA having a molecular weight of from about 400 Daltons to about 50,000 Daltons are useful in the area of tissue repair, where promotion of angiogenesis is required.
- Pharmaceutical compositions containing HA having a molecular weight between about 2 x 10 6 and about 3 x 10 6 Daltons can be administered to human or animal subjects to inhibit the formation of hypertrophic scars and keloids arising at wound sites resulting from injury or surgical intervention.
- compositions containing HA having a molecular weight greater than about 500,000 Daltons can be administered intraarticularly for the treatment of arthritis.
- formulations based on HA having a molecular weight greater than about 750,000 Daltons can be used in ophthamology.
- compositions can be applied topically to the wound site in the form of a liquid, cream, gel, ointment, spray, wound dressing, medicated biomaterial such as a film, gauze, threads, etc., or in the form of an intradermal injection at the time of wound formation or suturing.
- Doses of high molecular weight HA depend on the individual need of the patient, on the desired effect, and on the route of administration, and can typically be in the range of from about 0.1 mg to about 100 mg per inch or square inch of incision or wound, respectively.
- the administration of these pharmaceutical compositions to the wound site can be continued on a daily basis as required until such time as the healing process has been completed in order to avoid scar or keloid formation.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20699/95A AU2069995A (en) | 1994-03-11 | 1995-03-10 | Enzymatic preparation of polysaccharides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITPD94000042 | 1994-03-11 | ||
IT1994PD000042A IT1268954B1 (en) | 1994-03-11 | 1994-03-11 | PROCESS FOR THE PREPARATION OF HYALURONIC ACID BY MEANS OF ENZYMATIC SYNTHESIS AND RELATED PHARMACEUTICAL COMPOSITIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995024497A2 true WO1995024497A2 (en) | 1995-09-14 |
WO1995024497A3 WO1995024497A3 (en) | 1995-11-16 |
Family
ID=11390593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/000935 WO1995024497A2 (en) | 1994-03-11 | 1995-03-10 | Enzymatic preparation of polysaccharides |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2069995A (en) |
IT (1) | IT1268954B1 (en) |
WO (1) | WO1995024497A2 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020061A1 (en) * | 1995-11-30 | 1997-06-05 | The Scripps Research Institute | Synthesis of hyaluronic acid |
WO1998037222A1 (en) * | 1997-02-22 | 1998-08-27 | Uhlenküken, Jochen | Method for reversible immobilizing oligo- and/or polysaccharides |
US6020484A (en) * | 1995-12-20 | 2000-02-01 | Fidia Advanced Biopolymers S.R.L. | Process for preparing a hyaluronic acid fraction having a low polydispersion index |
WO2000027437A2 (en) * | 1998-11-11 | 2000-05-18 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
WO2001002032A1 (en) * | 1999-06-30 | 2001-01-11 | Novartis Ag | Ophthalmic molding |
EP1175157A1 (en) * | 2000-02-03 | 2002-01-30 | KBP Co., Ltd | Low molecular weight polymannuronate |
WO2004033472A1 (en) * | 2002-10-09 | 2004-04-22 | Westfälische Wilhelms-Universität Münster | Method for producing monomer uronic acids, especially d- mannuronic acid and d-guluronic acid and derivatives thereof, and the use of the same as medicaments |
DE10247073A1 (en) * | 2002-10-09 | 2004-04-22 | Westfälische Wilhelms-Universität Münster | Monomeric uronic acid compound production, for use e.g. as immunosuppressive, antirheumatic or cardiovascular agents, by hydrolyzing bacterially produced polyuronic acid |
AU774722B2 (en) * | 1998-04-02 | 2004-07-08 | Board Of Regents Of The University Of Oklahoma, The | Polymer grafting by polysaccharide synthases |
US6833264B1 (en) | 1997-10-31 | 2004-12-21 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses therof |
US6852514B2 (en) | 1994-07-01 | 2005-02-08 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
US6951743B2 (en) | 1997-10-31 | 2005-10-04 | University Of Oklahoma Board Of Regents | Hyaluronan synthase genes and expression thereof in bacillus hosts |
US6987023B2 (en) | 1998-04-02 | 2006-01-17 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7029880B2 (en) | 1997-07-23 | 2006-04-18 | The Board Of Regents Of The University Of Oklahoma | Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis |
US7060469B2 (en) | 1998-04-02 | 2006-06-13 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
US7091008B1 (en) | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7094581B2 (en) | 1998-10-26 | 2006-08-22 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthases and methods of making and using same |
US7223571B2 (en) | 1998-04-02 | 2007-05-29 | The Board Of Regents Of The Universtiy Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
US7462606B2 (en) | 2002-03-12 | 2008-12-09 | Fidia Farmaceutici S.P.A. | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
US7534589B2 (en) | 1999-11-10 | 2009-05-19 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
EP2072032A1 (en) * | 2007-12-17 | 2009-06-24 | Medichem S.r.L. | Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor |
US7642071B2 (en) | 1999-04-01 | 2010-01-05 | The Board Of Regents Of The University Of Oklahoma | Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts |
US7741091B2 (en) | 1998-04-02 | 2010-06-22 | The Board Of Regents Of The University Of Oklahoma | Methods of producing hyaluronic acid and chimeric and hybrid glycosaminoglycan polymers |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9896518B2 (en) | 2007-11-13 | 2018-02-20 | Bio-Technology General (Israel) Ltd. | Dilute filtration sterilization process for viscoelastic biopolymers |
CN111676258A (en) * | 2020-07-13 | 2020-09-18 | 南京恒道医药科技有限公司 | Method for continuously preparing and separating sodium hyaluronate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0144019A2 (en) * | 1983-11-25 | 1985-06-12 | Miles Inc. | Ultrapure hyaluronic acid and method of making it |
WO1992016640A1 (en) * | 1991-03-18 | 1992-10-01 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
WO1993008205A1 (en) * | 1991-10-15 | 1993-04-29 | The Scripps Research Institute | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose |
WO1994001468A1 (en) * | 1992-07-03 | 1994-01-20 | M.U.R.S.T., Italian Ministry For Universities And Scientific And Technological Research | Hyaluronic acid and derivatives thereof in interpenetrating polymer networks (ipn) |
-
1994
- 1994-03-11 IT IT1994PD000042A patent/IT1268954B1/en active IP Right Grant
-
1995
- 1995-03-10 AU AU20699/95A patent/AU2069995A/en not_active Abandoned
- 1995-03-10 WO PCT/EP1995/000935 patent/WO1995024497A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0144019A2 (en) * | 1983-11-25 | 1985-06-12 | Miles Inc. | Ultrapure hyaluronic acid and method of making it |
WO1992016640A1 (en) * | 1991-03-18 | 1992-10-01 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
WO1993008205A1 (en) * | 1991-10-15 | 1993-04-29 | The Scripps Research Institute | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose |
WO1994001468A1 (en) * | 1992-07-03 | 1994-01-20 | M.U.R.S.T., Italian Ministry For Universities And Scientific And Technological Research | Hyaluronic acid and derivatives thereof in interpenetrating polymer networks (ipn) |
Non-Patent Citations (5)
Title |
---|
ANALYTICAL BIOCHEMISTRY, vol.202, pages 215 - 238 ICHIKAWA ET AL. 'Enzyme-catalysed oligosaccharide synthesis' cited in the application * |
BIOCHEM. J., vol.211, pages 181 - 189 PREHM P. 'Synthesis of hyaluronate in differentiated teratocarcinoma cells : characterization of the synthase' cited in the application * |
J. BIOL. CHEM., vol.244, no.2, 25 January 1969 pages 236 - 246 STOOLMILLER ET AL. 'The biosynthesis of hyaluronic acid by Streptococcus' * |
J. BIOL. CHEM., vol.254, no.14, 25 July 1979 pages 6252 - 6261 SUGAHARA ET AL. 'Biosynthesis of hyaluronic acid by Streptococcus' cited in the application * |
J. ORG. CHEM., vol.47, pages 5416 - 5418 WONG ET AL. 'Enzyme-catalyzed synthesis of N-acetyllactosamine with in-situ regeneration of uridine-5'-diphosphate-glucose and uridine-5'-diphosphate galactose' * |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091008B1 (en) | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7026159B2 (en) | 1994-07-01 | 2006-04-11 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
US7109011B2 (en) | 1994-07-01 | 2006-09-19 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7087413B2 (en) | 1994-07-01 | 2006-08-08 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7504246B2 (en) | 1994-07-01 | 2009-03-17 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US6855502B2 (en) | 1994-07-01 | 2005-02-15 | Paul H. Weigel | Hyaluronate synthase gene and uses thereof |
US7060466B2 (en) | 1994-07-01 | 2006-06-13 | The Board Of Regents Of The University Of Oklahoma | Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene |
US8735102B2 (en) | 1994-07-01 | 2014-05-27 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7229796B2 (en) | 1994-07-01 | 2007-06-12 | Univ Oklahoma State | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7115405B2 (en) | 1994-07-01 | 2006-10-03 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US6991921B2 (en) | 1994-07-01 | 2006-01-31 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7166450B2 (en) | 1994-07-01 | 2007-01-23 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7153677B2 (en) | 1994-07-01 | 2006-12-26 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7141409B2 (en) | 1994-07-01 | 2006-11-28 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US6852514B2 (en) | 1994-07-01 | 2005-02-08 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
WO1997020061A1 (en) * | 1995-11-30 | 1997-06-05 | The Scripps Research Institute | Synthesis of hyaluronic acid |
US6020484A (en) * | 1995-12-20 | 2000-02-01 | Fidia Advanced Biopolymers S.R.L. | Process for preparing a hyaluronic acid fraction having a low polydispersion index |
EP0861903A1 (en) * | 1997-02-22 | 1998-09-02 | Lansing, Manfred | Method for reversible immobilizing oligo and/or polysaccharides |
WO1998037222A1 (en) * | 1997-02-22 | 1998-08-27 | Uhlenküken, Jochen | Method for reversible immobilizing oligo- and/or polysaccharides |
US7029880B2 (en) | 1997-07-23 | 2006-04-18 | The Board Of Regents Of The University Of Oklahoma | Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis |
US6833264B1 (en) | 1997-10-31 | 2004-12-21 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses therof |
US6951743B2 (en) | 1997-10-31 | 2005-10-04 | University Of Oklahoma Board Of Regents | Hyaluronan synthase genes and expression thereof in bacillus hosts |
US6987023B2 (en) | 1998-04-02 | 2006-01-17 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7223571B2 (en) | 1998-04-02 | 2007-05-29 | The Board Of Regents Of The Universtiy Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
US7060469B2 (en) | 1998-04-02 | 2006-06-13 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
US7232684B2 (en) | 1998-04-02 | 2007-06-19 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7604973B2 (en) | 1998-04-02 | 2009-10-20 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7741091B2 (en) | 1998-04-02 | 2010-06-22 | The Board Of Regents Of The University Of Oklahoma | Methods of producing hyaluronic acid and chimeric and hybrid glycosaminoglycan polymers |
AU774722B2 (en) * | 1998-04-02 | 2004-07-08 | Board Of Regents Of The University Of Oklahoma, The | Polymer grafting by polysaccharide synthases |
US7579173B2 (en) | 1998-04-02 | 2009-08-25 | The Board Of Regents Of The University Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using the same |
US7094581B2 (en) | 1998-10-26 | 2006-08-22 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthases and methods of making and using same |
US7575904B2 (en) | 1998-11-11 | 2009-08-18 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
JP2002529064A (en) * | 1998-11-11 | 2002-09-10 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ | Polymer grafting with polysaccharide synthase |
US6444447B1 (en) | 1998-11-11 | 2002-09-03 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
WO2000027437A3 (en) * | 1998-11-11 | 2000-07-20 | Univ Oklahoma | Polymer grafting by polysaccharide synthases |
WO2000027437A2 (en) * | 1998-11-11 | 2000-05-18 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
US7642071B2 (en) | 1999-04-01 | 2010-01-05 | The Board Of Regents Of The University Of Oklahoma | Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts |
US6468667B1 (en) | 1999-06-30 | 2002-10-22 | Novartis Ag | Ophthalmic molding |
WO2001002032A1 (en) * | 1999-06-30 | 2001-01-11 | Novartis Ag | Ophthalmic molding |
US7534589B2 (en) | 1999-11-10 | 2009-05-19 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
EP1175157A4 (en) * | 2000-02-03 | 2003-05-14 | Kbp Co Ltd | Low molecular weight polymannuronate |
US6747015B2 (en) | 2000-02-03 | 2004-06-08 | Kbp Co., Ltd. | Low molecular weight polymannuronate |
EP1175157A1 (en) * | 2000-02-03 | 2002-01-30 | KBP Co., Ltd | Low molecular weight polymannuronate |
US8178499B2 (en) | 2002-03-12 | 2012-05-15 | Fidia Farmaceutici S.P.A. | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
US8178663B2 (en) | 2002-03-12 | 2012-05-15 | Fidia Farmaceutici S.P.A. | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
US7462606B2 (en) | 2002-03-12 | 2008-12-09 | Fidia Farmaceutici S.P.A. | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring |
DE10247073A1 (en) * | 2002-10-09 | 2004-04-22 | Westfälische Wilhelms-Universität Münster | Monomeric uronic acid compound production, for use e.g. as immunosuppressive, antirheumatic or cardiovascular agents, by hydrolyzing bacterially produced polyuronic acid |
WO2004033472A1 (en) * | 2002-10-09 | 2004-04-22 | Westfälische Wilhelms-Universität Münster | Method for producing monomer uronic acids, especially d- mannuronic acid and d-guluronic acid and derivatives thereof, and the use of the same as medicaments |
DE10247073B4 (en) * | 2002-10-09 | 2010-08-05 | Mirshafiey, Abbas, Prof. Dr. | Process for the preparation of monomeric uronic acids, in particular D-mannuronic acid and D-guluronic acid and their use as medicaments |
US9896518B2 (en) | 2007-11-13 | 2018-02-20 | Bio-Technology General (Israel) Ltd. | Dilute filtration sterilization process for viscoelastic biopolymers |
WO2009077094A1 (en) * | 2007-12-17 | 2009-06-25 | Medichem S.R.L. | Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor |
EP2072032A1 (en) * | 2007-12-17 | 2009-06-24 | Medichem S.r.L. | Method for the intracellular regeneration of hyaluronic acid and cosmetic composition therefor |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
CN111676258A (en) * | 2020-07-13 | 2020-09-18 | 南京恒道医药科技有限公司 | Method for continuously preparing and separating sodium hyaluronate |
Also Published As
Publication number | Publication date |
---|---|
AU2069995A (en) | 1995-09-25 |
WO1995024497A3 (en) | 1995-11-16 |
ITPD940042A1 (en) | 1995-09-11 |
ITPD940042A0 (en) | 1994-03-11 |
IT1268954B1 (en) | 1997-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995024497A2 (en) | Enzymatic preparation of polysaccharides | |
US7060466B2 (en) | Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene | |
O'Regan et al. | Molecular mechanisms and genetics of hyaluronan biosynthesis | |
US9200024B2 (en) | Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases | |
AU2008202651B2 (en) | Hyaluronan synthase genes and expression thereof | |
US8735102B2 (en) | Hyaluronan synthase genes and expression thereof in Bacillus hosts | |
US6951743B2 (en) | Hyaluronan synthase genes and expression thereof in bacillus hosts | |
US7029880B2 (en) | Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis | |
US7060469B2 (en) | Polymer grafting by polysaccharide synthases | |
CA2536016C (en) | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same | |
US20160053290A1 (en) | Production of Defined Monodisperse Heparosan Polymers and Unnatural Polymers with Polysaccharide Synthases | |
Class et al. | Patent application title: Production of Defined Monodisperse Heparosan Polymers and Unnatural Polymers with Polysaccharide Synthases Inventors: Paul L. Deangelis (Edmond, OK, US) Paul L. Deangelis (Edmond, OK, US) Alison Sismey-Ragatz (Cassville, WI, US) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ CZ DE DK EE ES FI FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ CZ DE DK EE ES FI FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 704540 Date of ref document: 19970127 Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |